Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics (CRSP) is a clinical-stage biopharmaceutical leader pioneering CRISPR/Cas9 gene editing therapies for serious diseases. This page aggregates official announcements, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and researchers will find timely updates on therapeutic programs targeting hemoglobinopathies, oncology, and autoimmune disorders. Track regulatory milestones, partnership announcements with industry leaders, and financial performance reports. All content is curated to meet investor needs for decision-making clarity.
Key updates include progress in allogeneic CAR-T cell therapies, hemoglobinopathy treatment approvals, and manufacturing scale-up initiatives. Bookmark this page for structured access to CRISPR Therapeutics' latest scientific advancements and business developments.
CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in several investor conferences in March 2022. The schedules are as follows:
- Cowen 42nd Annual Health Care Conference on March 7 at 10:30 a.m. ET.
- Barclays Global Healthcare Conference on March 17 at 10:15 a.m. ET.
- Oppenheimer 32nd Annual Healthcare Conference on March 24 at 11:00 a.m. ET.
Live webcasts will be available on the company's website, with replays accessible for 14 days post-event.
CRISPR Therapeutics (Nasdaq: CRSP) reported a productive 2021, advancing its gene-editing therapies. More than 70 patients have been dosed with CTX001 for beta thalassemia and sickle cell disease, with regulatory submissions expected in late 2022. The company initiated the pivotal trial for CTX110 targeting B-cell malignancies, expecting further data this year. Financially, total revenue surged to $913.1 million from $0.5 million YoY, driven by Vertex collaborations. However, net loss widened to $141.2 million in Q4 2021, emphasizing the costs of R&D investments.
CRISPR Therapeutics (Nasdaq: CRSP) announced that its senior management team will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 p.m. ET. The event will be accessible via a live webcast on the company’s Investors section of its website. Following the event, a replay will be available for 14 days. CRISPR Therapeutics focuses on developing gene-based medicines using CRISPR/Cas9 technology to address serious diseases, with collaborations alongside industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics announced the first patient has been dosed in a Phase 1 clinical trial for VCTX210, a gene-edited, stem-cell therapy aimed at treating type 1 diabetes. Developed in partnership with ViaCyte, VCTX210 is designed to produce insulin while evading immune rejection. The trial will assess safety, tolerability, and immune evasion capabilities. If successful, VCTX210 could provide a transformative treatment option for diabetes patients without the need for immunosuppression.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences in December 2021. The first event is the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:35 p.m. ET. The second is the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021, at 1:00 p.m. ET. Webcast access will be available on CRISPR's website, with replays archived for 14 days post-event. CRISPR is focused on developing transformative gene-based medicines using its CRISPR/Cas9 platform.
CRISPR Therapeutics (Nasdaq: CRSP) announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110™, its allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. This designation highlights the promising clinical data and aims to expedite drug development and review processes. CTX110 is being evaluated in the CARBON trial for safety and efficacy. The RMAT designation facilitates discussions with the FDA and potential accelerated approval, emphasizing the transformative potential of CTX110 for patients with hematological malignancies.
CRISPR Therapeutics and ViaCyte have received approval from Health Canada for their Clinical Trial Application (CTA) for VCTX210, a gene-edited therapy aimed at treating type 1 diabetes (T1D). This therapy promises to be immune-evasive and stem cell-derived. Patient enrollment is anticipated to begin by the end of this year. The Phase 1 trial will evaluate VCTX210's safety, tolerability, and immune evasion. This milestone marks a significant step in developing gene-edited stem cell therapies for diabetes.
CRISPR Therapeutics reported significant progress across its clinical portfolio in the third quarter of 2021. Target enrollment for CTX001 trials in beta thalassemia and sickle cell disease has been achieved, supporting regulatory submissions planned for late 2022. Positive results from the Phase 1 CARBON trial for CTX110 indicate promising efficacy for B-cell malignancies, with overall response rates demonstrating competitive profiles compared to existing therapies. However, the company reported a net loss of $127.2 million for the quarter, up from $92.4 million a year prior.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two upcoming virtual investor conferences. The Credit Suisse 30th Annual Healthcare Conference is scheduled for November 8, 2021, at 1:00 p.m. ET, followed by the Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-event. CRISPR Therapeutics specializes in gene editing using its CRISPR/Cas9 platform, addressing serious diseases through innovative therapeutics.
CRISPR Therapeutics (Nasdaq: CRSP) appointed Brendan Smith as Chief Financial Officer, effective immediately. Smith succeeds Michael Tomsicek, who is retiring after four years, and will assist in a smooth transition until the end of 2021. Smith brings over 20 years of experience, previously serving as CFO of Translate Bio, which was acquired by Sanofi for $3.2 billion. CEO Samarth Kulkarni highlighted Smith's expertise during a critical growth phase for CRISPR Therapeutics, which focuses on gene-based medicines for serious diseases using CRISPR/Cas9 technology.
